secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001213900-23-024969
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive reports 2022 net loss of $18.1M, cash $0.5M; closes $30M fundraise; NDA on track for mid-2023
--------------------------------------------------------------------------------

- Net loss for 2022 was $18.1M ($1.20/sh) vs $10.0M ($0.86/sh) in 2021.
- Cash and equivalents $0.5M at Dec 31, 2022; closed $30M private placement with up to $130M total.
- Renazorb pivotal BE study met primary endpoint; NDA submission on track for mid-2023.
- Exclusive license with Lotus Pharma for Renazorb in South Korea.
- R&D expenses $12.4M (up 103% YoY) driven by $6.5M in development services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023024969/0001213900-23-024969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023024969/ea176065-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-024969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer